Who benefits from weight-loss medication

GLP-1 medications have had a cultural moment that has caused problems. A drug designed to treat the biological problem of obesity has been marketed, in some quarters, as a cosmetic aid for people at weights where it is clinically inappropriate. We write this article to be clear about who actually benefits, because that matters for safety, cost, and the right expectation of results.

The formal prescribing criteria

In the UK, NICE guidance and the MHRA licence for Wegovy and Mounjaro specify that prescribing is appropriate for:

Adults with a BMI of 30 kg/m² or higher (obesity).

Adults with a BMI of 27 kg/m² or higher AND at least one weight-related health condition: type 2 diabetes, pre-diabetes, high blood pressure, cardiovascular disease, sleep apnoea, or non-alcoholic fatty liver disease.

Adults with a BMI of 35 kg/m² or higher in the presence of any of the above are considered a priority for treatment.

Outside these thresholds, private prescribing is legally possible but clinically harder to justify. We apply the NICE criteria in our assessments because they represent the evidence base for safety and benefit.

The biological argument

People outside the clinical criteria often ask why they should not take GLP-1 medication anyway if they want to lose 5kg. The honest answer has several parts.

At BMI below 27, side effect risk (pancreatitis, gallstones) sits on roughly the same scale as the modest weight-loss benefit. The risk-benefit math becomes less favourable.

At BMI below 27, the pre-treatment appetite-regulation biology is generally not as disordered as in obesity. Medications that correct an undisturbed system can produce over-correction: unwanted weight loss, loss of lean mass, nutritional deficiency, and longer-term metabolic effects we do not fully understand.

Weight loss from a lean starting point is not the same problem as weight loss from obesity. The two have different drivers, different treatments, and different appropriate outcomes.

When we recommend starting

We typically recommend starting GLP-1 treatment when all four of the following are true:

Your BMI is 30 or above (or 27+ with a weight-related comorbidity).

You have tried structured lifestyle changes for at least three months without meaningful sustained progress.

You do not have any contraindicating condition (see next section).

You are committed to at least 12 months of treatment and ongoing lifestyle work alongside medication.

The last point matters. GLP-1 medications work best when treated as a one- to two-year intervention, not a one-month reset. Stopping after two months of high-dose treatment tends to produce rapid rebound. We would rather not prescribe than prescribe without this understanding.

When we do not prescribe

We will not prescribe GLP-1 medication in any of the following situations:

Personal history of medullary thyroid cancer or multiple endocrine neoplasia type 2.

Personal history of pancreatitis.

Currently pregnant, planning pregnancy in the next six months, or breastfeeding.

Type 1 diabetes (GLP-1s are not appropriate for type 1).

Serious eating disorder (anorexia or bulimia) active in the last two years.

Age under 18.

These are clear stop-signs. Where we are uncertain - for example, borderline BMI of 26-27 without a comorbidity, or a history of pancreatitis that was clearly alcohol-related and not spontaneous - we discuss the situation openly and decide together.

When we think another approach is better

In some situations we will suggest an alternative before medication.

If you have never had structured dietary or lifestyle support, a properly-run programme (the NHS Tier 3 service, the Oviva NHS programme, or a private nutritional consultation) can produce meaningful weight loss without medication.

If your BMI is in the 27-30 range and you do not have a weight-related comorbidity, a full metabolic assessment (bloods, body composition, CV risk) may show that your weight is not currently causing clinical harm. In that situation we generally advise against starting medication.

If your primary concern is body-composition (visible muscle definition, athletic performance) rather than clinically-meaningful weight loss, GLP-1 medications are not the right tool.

The honest summary

GLP-1 medications transform the lives of people for whom they are clinically appropriate. They are not a weight-control tool for people whose weight is not affecting their health. The assessment exists to make sure you are in the first group, not the second.

If you are unsure which group you are in, the assessment is the right next step and we will tell you honestly what we think.

Ready to start?

If this article has made you think medication might help, the next step is a short consultation with one of our weight-management doctors.

Begin your consultation at this link. Online in 30 minutes, or in person at Westfield London.